4.5 Review

Pulmonary hypertension in left heart disease

期刊

EUROPEAN RESPIRATORY REVIEW
卷 21, 期 126, 页码 338-346

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09059180.00004612

关键词

Left heart disease; preserved ejection fraction; pulmonary hypertension

资金

  1. Actelion Pharmaceuticals Ltd (Allschwil, Switzerland)

向作者/读者索取更多资源

Pulmonary hypertension (PH) is a frequent complication of left heart disease arising from a wide range of cardiac disorders. In the clinical classification, PH associated with left heart disease is classified as Group 2, which includes left heart systolic dysfunction, left heart diastolic dysfunction and left heart valvular disease. In the past, rheumatic mitral valve disease was the most common cause of PH in left heart disease; however, today it is more likely to be associated with hypertensive and/ or ischaemic heart disease. As the incidence of these conditions is increasing, the number of patients presenting with PH is also increasing and, today, left heart disease represents the most frequent cause of PH. The development of PH in patients with left heart disease is associated with poor prognosis. However, despite the increasingly large number of patients affected and the impact of PH on outcome, there are currently no specific treatment options for these patients. This review gives an overview of the pathophysiology and epidemiology of PH associated with left heart disease, and discusses the challenges associated with its management and treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据